CEREGIN SOLUTION 30ML

Co-Dergocrine mesylate liquid primarily acts by influencing the hypothalamic-pituitary-adrenal (HPA) axis and the central nervous system. It contains a combination of ergocornine-8-carboxylate and ergocristine-8-carboxylate, which are partial agonists of dopamine receptors, particularly D2 receptors. By binding to these receptors, co-dergocrine mesylate liquid exerts dopamine-like effects, helping to regulate the release of prolactin and other hormones. This mechanism is thought to contribute to its therapeutic effects, particularly in conditions where hormonal imbalances play a role. The dopamine receptor partial agonism may also have implications for modulating neurotransmission and influencing various physiological processes regulated by dopamine in the central nervous system.

Co-Dergocrine Mesylate

Gonadotropin.

Liquid

The following are the uses of Co-Dergocrine Mesylate Liquid:

• Used for treating menopausal symptoms such as hot flashes, night sweats, and vaginal dryness.
• Used for managing hormone-related mood changes, including depression and irritability during menopause.
• Used for alleviating vaginal discomfort and pain during sexual intercourse due to menopause-related changes.
• Used for improving energy levels and reducing fatigue associated with menopause.
• Used for supporting bone health and reducing the risk of osteoporosis in menopausal women.
• Used for managing sleep disturbances and insomnia related to hormonal fluctuations during menopause.
• Used for addressing urinary symptoms like urgency and frequency that may occur during menopause.
• Used for potentially improving cognitive function and memory, which can be affected by hormonal changes.

In the case of an overdose of Co-Dergocrine Mesylate Liquid, the severity of symptoms can vary. Individuals may experience heightened side effects such as nausea, vomiting, dizziness, or headaches. It is crucial to seek medical advice promptly and inform healthcare professionals about the specific details of the overdose, including the amount ingested and the time of consumption. Timely intervention can help manage any adverse reactions effectively.

In the case of a missed dose of Co-Dergocrine Mesylate Liquid, it is important to take the medication as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not double the dose to make up for a missed one, as this may increase the risk of side effects. If you frequently miss doses, consider setting reminders or using a pill organizer to help you stay on track with your medication routine. Consult your healthcare provider if you have any concerns or questions regarding missed doses.

To administer Co-Dergocrine Mesylate Liquid, carefully measure the prescribed dosage using the provided measuring device, then take it orally as directed by your healthcare professional, typically once daily, with or without food, following the instructions on the prescription label or as advised by your doctor.

Here are the situations when Co-Dergocrine Mesylate Liquid should not be used:

• Allergic reaction Not recommended for individuals with a known or suspected allergy or sensitivity to Co-Dergocrine Mesylate or any of its components.
• Pregnancy Contraindicated in pregnant women as it may cause harm to the developing fetus.
• Breastfeeding Not suitable for women who are breastfeeding, as it can pass into breast milk.
• Liver disease Should be avoided in patients with severe liver impairment or liver disease.
• Kidney disease Not recommended for individuals with severe kidney disease or kidney failure.
• Uncontrolled hypertension Not suitable for patients with uncontrolled high blood pressure.
• Coronary heart disease Should be used with caution in patients with coronary heart disease or a history of heart attack.
• Cerebrovascular disease Contraindicated in individuals with cerebrovascular disease or a history of stroke.
• Peripheral vascular disease Not recommended for patients with peripheral vascular disease.
• Thrombophlebitis Should not be used in individuals with a history of thrombophlebitis (blood clots in the veins).
• Thromboembolic disorders Contraindicated in patients with a history of blood clots or thromboembolic disorders.
• Depression Use with caution in patients with a history of depression, as it may worsen symptoms.
• Migraine Not suitable for individuals with a history of migraine headaches.
• Pituitary tumor Should not be used in patients with a known or suspected pituitary tumor.
• Endocrine disorders Contraindicated in individuals with certain endocrine disorders, such as Cushing's syndrome or hyperprolactinemia.
• Uterine fibroids Use with caution in women with uterine fibroids.
• Endometriosis Not recommended for patients with endometriosis.

The side effects of Co-Dergocrine Mesylate Liquid may include:

• Nausea and vomiting
• Headaches
• Dizziness
• Gastrointestinal issues like abdominal pain and diarrhea
• Increased heart rate or palpitations
• Skin rashes or itching
• Sleep disturbances and insomnia
• Nasal congestion

Following are the precautions and warnings for Co-Dergocrine Mesylate Liquid:

• This medication should be used with caution in patients with a history of liver or kidney disease, as it may require dosage adjustments.
• Not recommended for individuals with a known allergy to Co-Dergocrine Mesylate or any of its components.
• Avoid alcohol consumption while taking this medication, as it may increase the risk of side effects.
• Patients should be monitored for signs of excessive androgenic effects, such as deepening of the voice, hirsutism, and acne.
• Co-Dergocrine Mesylate Liquid may cause dizziness or drowsiness; patients should avoid driving or operating heavy machinery until they know how the medication affects them.
• Not suitable for use in pregnant or breastfeeding women due to potential risks to the fetus or infant.
• Patients with a history of heart disease or blood clots should use this medication with caution, as it may increase the risk of cardiovascular events.
• It is important to regularly monitor blood pressure and blood sugar levels while on this medication, especially in diabetic patients.

Following are the drug interactions for Co-Dergocrine Mesylate Liquid:

• Co-administration with drugs metabolized by CYP450 enzymes may result in altered plasma levels of either drug, as Co-Dergocrine Mesylate can inhibit CYP1A2, CYP2C9, and CYP3A4 isoenzymes.
• The effectiveness of oral anticoagulants like warfarin may be increased, requiring careful monitoring of prothrombin time and adjustment of dosage.
• Concomitant use with antihypertensive medications can lead to additive effects and potentially cause hypotension.
• Co-Dergocrine Mesylate may enhance the sedative effects of central nervous system depressants, including alcohol, benzodiazepines, and opioids.
• Caution is advised when using with tricyclic antidepressants, as it may increase their plasma concentrations and potential side effects.
• It can interact with certain anti-diabetic medications, affecting blood glucose control. Regular monitoring of blood sugar is recommended.
• The absorption of Co-Dergocrine Mesylate may be reduced when taken with aluminum-containing antacids, leading to decreased efficacy.

Following are the food interactions to consider with Co-Dergocrine Mesylate Liquid:

• Grapefruit consumption should be limited or avoided as it can interfere with the drug's metabolism, potentially leading to increased side effects.
• Alcohol intake should be minimized or avoided. Alcohol may exaggerate the sedative effects of Co-Dergocrine Mesylate, causing enhanced drowsiness and dizziness.
• Caffeine-rich foods and beverages might need to be reduced as they can potentially interact with the medication, affecting its efficacy and increasing the risk of side effects.
• High-sodium foods should be consumed in moderation, as Co-Dergocrine Mesylate may interact with sodium levels in the body.
• It is advisable to maintain a balanced diet, ensuring adequate intake of vitamins and minerals, as the medication may impact nutrient absorption.
• Avoid excessive consumption of fatty foods, as they can potentially influence the absorption and distribution of the drug.
• Always consult your healthcare provider for personalized advice on diet and specific food restrictions while taking this medication.
• Stay hydrated by drinking enough water, especially if you experience increased thirst as a side effect of the medication.

The storage and disposal of Co-Dergocrine Mesylate Liquid require specific attention to ensure its integrity and safety. Store the liquid in a cool and dry environment, preferably at room temperature, ensuring protection from direct sunlight and moisture. Keep the medication in its original container, tightly sealed, to prevent contamination. Avoid extreme temperatures, such as those near heat sources or in bathrooms, as they can impact the liquid's stability. Regularly check the expiration date, and if the liquid is no longer needed or has expired, proper disposal is crucial. Do not dispose of it through household waste or plumbing systems; instead, consult a pharmacist or healthcare professional for guidance on safe disposal methods, ensuring that it is kept away from children and pets.

Following are the quick tips for Co-Dergocrine Mesylate Liquid:

• Follow the prescription guidelines provided by your doctor for the best outcomes.
• Administer the liquid as directed, ensuring accuracy in dosage.
• Store the medication at room temperature, away from direct sunlight and moisture.
• Avoid sharing your medication with others, even if they have similar symptoms.
• Consult your doctor if you experience any unusual side effects or allergic reactions.
• Ensure you complete the full course of medication as prescribed.
• Inform your healthcare provider about any other medications you are taking to prevent potential interactions.